drug

Cognitive Behavioral Group Therapy

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
BEHAVIORAL
Pre-approval / investigational in the US
Developed by National Institute on Drug Abuse (NIDA)
2 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
BEHAVIORAL

Indications

Trials

2
Specialized Treatment Early in Psychosis (STEP)
NCT00309452—Completed
Safety and Effectiveness of Sustained Release Bupropion in Treating Individuals With Schizophrenia Who Smoke
NCT00307203Phase 4Completed

KOLs & investigators

3
A. Eden Evins, MD, MPHKOL score 5
Scott Woods, M.D.
Vinod H Srihari, M.D.

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
National Institute on Drug Abuse (NIDA)
company
trial
Specialized Treatment Early in Psychosis (STEP)
NA
trial
Safety and Effectiveness of Sustained Release Bupropion in Treating Individuals With Schizophrenia Who Smoke
PHASE4
trial
indication
Schizophrenia
indication
Tobacco-Use Disorder
indication
Schizophrenia Spectrum and Other Psychotic Disorders
indication
Smoking Cessation
indication
KOL
A. Eden Evins, MD, MPH
KOL score 5
person
Scott Woods, M.D.
KOL score —
person
Vinod H Srihari, M.D.
KOL score —
person